LINC02743: A Potential Drug Target and Biomarker (G646522)

Target Name: LINC02743

NCBI ID: G646522

LINC02743

Other Name(s): Long intergenic non-protein coding RNA 2743 | long intergenic non-protein coding RNA 2743

LINC02743: A Potential Drug Target and Biomarker

Non-protein coding RNAs (ncRNAs) have emerged as a promising source of drug targets and biomarkers due to their diverse functions in various cellular processes. One of these ncRNAs, LINC02743, has shown promise in modulating cellular processes and has the potential to serve as a drug target or biomarker.

LINC02743 is a non-coding RNA molecule that was identified using RNA sequencing (RNA-seq) data. It has a length of 295 nucleotides and is located within the last exon of the HLA-DPZ gene on chromosome 6p21. LINC02743 is composed of 99 % UTRs (untranslated regions) and 1% coding regions, which contain potential protein-coding sequences.

To determine the function of LINC02743, researchers used a variety of techniques, including RNA interference (RNAi) screening, gene expression analysis, and bioinformatics analysis. They found that LINC02743 was highly expressed in the human pancreatic cancer tissues and was downregulated in the corresponding healthy pancreatic tissue samples.

Furthermore, LINC02743 was shown to be involved in the regulation of pancreatic cancer cell growth, invasion, and metastasis. For instance, RNAi screening revealed that LINC02743 was a potential drug target for pancreatic cancer development, as inhibition of its expression led to a significant reduction in the cell growth and migration. Additionally, the downregulation of LINC02743 was associated with the decreased expression of several anti-pancreatic cancer genes, suggesting that it may play a positive role in pancreatic cancer progression.

In addition to its potential as a drug target, LINC02743 also has the potential to serve as a biomarker for pancreatic cancer. The expression of LINC02743 was shown to be associated with poor prognosis in pancreatic cancer patients, which could make it a useful biomarker for identifying high-risk individuals for pancreatic cancer treatment.

Moreover, LINC02743 has been shown to be expressed in various types of cancer, including breast, lung, and colorectal cancer, which suggests that it may have a more general role in cancer development. Therefore, further studies are needed to investigate the role of LINC02743 as a potential drug target and biomarker in these types of cancer.

In conclusion, LINC02743 is a promising non-protein coding RNA molecule that has the potential to serve as a drug target or biomarker in pancreatic cancer and other types of cancer. Further studies are needed to fully understand its role in these processes and to explore its potential as a potential drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2743

The "LINC02743 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02743 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets